Navigation Links
ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Date:8/24/2007

LEUVEN, Belgium, August 24 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the seven month period ending 30 June 2007. During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights

- Successful placing of a total of 5,166,517 shares, which increased the company's free float to 70%, and led to an improvement in stock liquidity. As part of this placement, ThromboGenics issued 2,214,030 new shares raising a total of EUR23.9m. These new funds have strengthened ThromboGenics financial position, and will allow it to continue to advance the development of its product portfolio and strengthen its operations. The company's cash position amounted to EUR49.3m as of 30 June 2007.

- Further progress with microplasmin for ophthalmic indications. Initiation of a Phase IIb clinical trial of microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection) in the United States, as well as the initiation of two Phase IIa clinical trials of microplasmin in Europe, for Vitreomacular traction and diabetic macular edema (MIVI IIT and MIVI II, respectively).

- Progressed TB-402 (anti-factor VIII) into man, in collaboration with BioInvent International. TB-402 is being developed as a potential anti-coagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation.

Financial summary

- For the December 2006 to June 2007 period, revenues amounted to EUR1.3m, mainly coming from out-licensing. Operating expenses were EUR10.5m, the majority of which were due to R&D expenses related to the microplasmin clinical development program. The net loss for the period was EUR8.6m.

- As of 30 June 2007, ThromboGenics had EUR49.3m in cash and cash equivalents. This compared to
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. While schools combat low tech enrollment, are businesses contributing to IT workforce woes?
2. CIOs focus on the business case while facing authority erosion
3. Surgical products company wins Governors Business Plan Contest
4. Business plan finalists capture technology
5. Speaker announces business members of IT Task Force
6. The business case for software applications
7. Turbo Tax Online can teach new Web concepts a business lesson
8. Former Fiserv exec to enter Business Hall of Fame
9. What does business want from the schools? Some answers may be surprising
10. Shades of gray: Business impacts of an aging workforce
11. Connectures Maynard finds IT business opportunity in adversity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
(Date:5/4/2015)... Wheaton, Illinois (PRWEB) May 04, 2015 ... treatment options for patients with arm and hand ... rehabilitation exoskeleton at its Oakbrook Terrace network site. ... foundation, the Armeo®Spring is a highly-regarded treatment option ... In acquiring the Armeo®Spring, Marianjoy becomes one of ...
(Date:5/1/2015)... May 1, 2015 /CNW/ - Softchoice, a leading North American IT ... the proud recipient of two Cisco® Partner Summit Country awards. ... the Year and Security Partner of the Year for ... place this week in Montreal . ... two Cisco partner awards at this year,s conference," said ...
(Date:5/1/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , ... provide an overview and update on the company,s business at ... in Boston, Massachusetts . The ... 3:30 PM Eastern Time, and can be accessed via a ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2
... Wash., March 6 Cardiac Science,Corporation (Nasdaq: ... advanced cardiac diagnosis,resuscitation, rehabilitation, and informatics products, ... its leading product brands (Burdick(R),HeartCentrix(R), Powerheart(R), and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO ), "We believe ...
... March 5 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc.,("Dragon" ... BBSE: DRP), a leading,international pharmaceutical company today ... capacity for its core products 7ACA and,Clavulanic ... order to meet increasing,demand from its customers. ...
... Acura,Pharmaceuticals, Inc. (Nasdaq: ACUR ) reported 2007 fourth ... compared to net income,of $3.9 million, or $0.44 loss per ... below) for the same quarter in 2006.,For the year ended ... million, or $0.11 per share compared to a net loss ...
Cached Biology Technology:Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness 2Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness 3Cardiac Science Unveils Major Brand Change; Strategy to Lift Brand Awareness 4Dragon announces new product launch; increase in annual production output capacity 2Dragon announces new product launch; increase in annual production output capacity 3Dragon announces new product launch; increase in annual production output capacity 4Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations 2Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations 3Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations 4Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations 5Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations 6
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... found why women have an edge in keeping a healthier ... - at least before reaching menopause. Premenopausal women are ... in general, but afterward their risks are essentially the same ... Vascular Biology Center at the Medical College of Georgia. ...
... Sciences has awarded Arthur Grossman, of the Carnegie Institution,s ... Medal "in recognition of excellence in published research on ... the Helen P. Smith Fund. Grossman is ... about Chlamydomonas, a tiny green alga affectionately called Chlamy, ...
... This release is available in German . ... year as a result of pneumococcal infection, which causes ... and the elderly are especially at risk. Vaccines are ... and increasing resistance to antibiotics is making treatment more ...
Cached Biology News:Researchers may have found why women have an edge on salt-sensitive hypertension 2Carnegie's Arthur Grossman receives Gilbert Morgan Smith medal 2Deceiving cell walls 2
... The IHC Select Immunoperoxidase Secondary Detection System ... or goat IgG in the Primary Antibody. ... present in the specimen. Any excess antibody ... Antibody Reagent (conjugated to biotin) is added ...
... Protein Purification Protocols covers a wide range ... novice and experienced researchers in all areas ... excerpt from the books preface illustrates just ... your research library., The chapters introduce the ...
... long double stranded RNA (dsRNA) has been ... diverse group of organisms as well as ... to the inhibition of protein expression by ... messenger RNA (mRNA). Attempts to induce RNA ...
... movement counts, similar to an infrared beam break ... subjects at once, in two frames of reference, ... experimental group at once, and allow social interaction ... a variety of other spatial behavior situations, including ...
Biology Products: